BioMarin Pharmaceutical Inc. (BMRN) announced that its Phase 3 pivotal study CANOPY-HCH-3, of VOXZOGO (vosoritide) in children with hypochondroplasia met its primary and key secondary endpoints.
The randomized double-blind, placebo-controlled, multicenter trial enrolled 80 patients aged 3 to 17. Results showed a placebo-adjusted increase of 2.33 cm per year in annualized growth velocity (AGV) at week 52, exceeding the 1.57 cm per year improvement seen in VOXZOGO's prior achondroplasia study.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.